Articles: chronic.
-
Critical Care Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Diffuse alveolar hemorrhage (DAH) is associated with negative pressure pulmonary edema secondary to acute upper airway obstruction. There have been no associations with the upper airway obstruction of obstructive sleep apnea. Negative intrathoracic pressure leads to an increase in pulmonary vascular volume and pulmonary capillary transmural pressure, creating a risk of disruption of the alveolar-capillary membrane. We present a case of DAH in a patient on anticoagulation with positive anti-cardiolipin antibody and low level anti-dsDNA triggered by severe obstructive sleep apnea. ⋯ The following authors have nothing to disclose: Sadaf Mir, Silviana Marineci, Mary O'SullivanNo Product/Research Disclosure Information.
-
OSA & COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Healthcare costs are a major concern for individuals especially in the United States. The healthcare delivery system in the US is challenged with pressures to reduce costs while not diminishing access to high quality care. therefore ,we evaluated the impact of delayed diagnosis of OSA, on different co- morbidities, patient outcome and healthcare costs ⋯ The following authors have nothing to disclose: Ahmed FadilNo Product/Research Disclosure Information.
-
Critical care medicine · Mar 2014
Multicenter Study Observational StudyAugmented Renal Clearance in the ICU: Results of a Multicenter Observational Study of Renal Function in Critically Ill Patients With Normal Plasma Creatinine Concentrations.
To describe the prevalence and natural history of augmented renal clearance in a cohort of recently admitted critically ill patients with normal plasma creatinine concentrations. ⋯ Augmented renal clearance appears to be a common finding in this patient group, with sustained elevation of creatinine clearance throughout the first week in ICU. Future studies should focus on the implications for accurate dosing of renally eliminated pharmaceuticals in patients with augmented renal clearance, in addition to the potential impact on individual clinical outcomes.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). The BEACON study evaluated the efficacy and safety of QVA149 compared with the concurrent administration of indacaterol and glycopyrronium (IND+GLY). ⋯ The study demonstrated that QVA149 provides benefits of dual bronchodilation in a single inhaler device, making it a more convenient treatment option for patients with moderate-to-severe COPDDISCLOSURE: Ronald Dahl: Consultant fee, speaker bureau, advisory committee, etc.: In the past 3 years, Professor Dahl has received compensation for consulting with Boehringer-Ingelheim, Novartis, Vectura, Roche, Elevation Pharma and Norpharma; has undertaken research funded by AstraZeneca, Boehringer- Ingelheim, C hiesi, GlaxoSmithKline, Novartis, ALK-Abello and Stallergenes; has participated in educational activities sponsored by AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, ALK-Abello, Novartis, Almirall. Dalal Jadayel: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Bronchiectasis PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Bronchiectasis are defined as permanent, abnormal dilation of bronchi and bronchioles. Laenec in 1819, the first described them as a very common disease before the age of antibiotics. Today is a minor problem in developed countries in opposition to developing countries. The purpose of this study is to determine the prevalence of bacteria in patients with non-CF bronquiectacias. ⋯ The following authors have nothing to disclose: Georgina Gramblicka, Daniela Visentini, Valeria Morandi, Maria Laura Grodnitzky, Gabriela Tabaj, Patricia Malamud, Ana Sangoy, Andrea Appendino, Laura Biglieri, Silvia GuaycocheaNo Product/Research Disclosure Information.